Ocugen financials
$1.09+5.83%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $4.1M | $6.0M | $2.5M | — | $43.0K | $0.00 |
| Gross profit | $4.4M | $4.1M | $6.0M | $2.5M | — | $43.0K | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | — |
| Operating income | -$62.9M | -$54.8M | -$65.5M | -$89.1M | -$58.0M | -$21.3M | -$14.2M |
| Net income | -$67.8M | -$54.1M | -$63.1M | -$86.8M | -$58.4M | -$34.4M | -$20.2M |
| Net margin | −1537.4% | −1333.0% | −1045.0% | −3488.9% | — | −79925.6% | — |
| Diluted EPS | $-0.23 | $-0.20 | $-0.26 | $-0.40 | $-0.30 | $-0.31 | $-1.46 |
| EBITDA | -$60.5M | -$52.8M | -$64.8M | -$88.6M | -$57.8M | -$21.2M | -$14.1M |
| Operating cash flow | -$57.0M | -$42.1M | -$62.1M | -$60.1M | -$47.9M | -$14.7M | -$16.9M |
| Free cash flow | -$57.1M | -$45.5M | -$72.5M | -$64.5M | -$48.9M | -$15.0M | -$16.9M |
| Diluted shares | 300.2M | 271.0M | 244.3M | 214.6M | 195.0M | 112.2M | 13.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.6M | $58.5M | $39.5M | $77.6M | $95.0M | $24.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $13.4M | $0.00 | — |
| Total debt | $28.8M | $28.7M | $2.8M | $2.3M | $1.7M | $2.1M |
| Total assets | $43.5M | $82.4M | $64.5M | $108.6M | $105.8M | $27.4M |
| Total liabilities | $55.7M | $52.8M | $24.0M | $34.7M | $9.9M | $5.8M |
| Shareholders' equity | -$12.2M | $29.6M | $40.6M | $74.0M | $95.8M | $21.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology